DRIO
DarioHealth Corp.
There isn't enough reported data to score DRIO yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
DRIO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
DRIO's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
DRIO PE Valuation
DRIO has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
DRIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect DRIO's losses to shrink, with revenue growing.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
DRIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$5.60 | +$33.20 |
| Q2 2024 | -$20.40 | +$21.40 |
| Q1 2024 | -$33.60 | +$11.40 |
| Q4 2023 | -$38.60 | +$12.20 |
NVO has the stronger earnings trend. Trailing diluted EPS is down 114% for DRIO versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
DRIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.3M | +6.1% |
| Q2 2026 | $5.2M | -3.6% |
| Q1 2026 | $5.6M | -17% |
| Q4 2025 | $5.2M | -31% |
| Q3 2025 | $5M | -33% |
| Q2 2025 | $5.4M | -14% |
| Q1 2025 | $6.8M | +17% |
| Q4 2024 | $7.6M | +110% |
DRIO's revenue is recovering but still below its 2022 peak: $5M last quarter, up 6.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -151% | +38 points |
| Q2 2026 | -125% | +46 points |
| Q1 2026 | -131% | +8.5 points |
| Q4 2025 | -164% | -10 points |
| Q3 2025 | -189% | -27 points |
| Q2 2025 | -171% | +88 points |
| Q1 2025 | -139% | +171 points |
| Q4 2024 | -153% | +240 points |
DRIO's operating margin was −151% last quarter, up 38 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over DRIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over DRIO on profitability, with a higher operating margin.
DRIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.6M | +$1.8M |
| Q2 2026 | -$6.1M | -$46K |
| Q1 2026 | -$6.1M | +$648K |
| Q4 2025 | -$5.9M | +$840K |
| Q3 2025 | -$7.4M | -$2K |
| Q2 2025 | -$6.1M | +$5.3M |
| Q1 2025 | -$6.7M | +$6.5M |
| Q4 2024 | -$6.8M | +$671K |
DRIO has burned cash in almost every quarter: −$24M over the past year, against −$27M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over DRIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
DRIO Net Leverage
DRIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
DRIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 19.8 | Oversold |
| Stochastic | 1.0 | Oversold |
DRIO's weekly RSI is 20 (oversold) and its Stochastic is 1 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
DRIO PE vs Healthcare Sector
DRIO has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
DRIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.31 | 62% below |
| 20 week MA | $6.07 | 73% below |
| 50 week MA | $8.02 | 79% below |
| 100 week MA | $10.7 | 85% below |
| 200 week MA | $28.9 | 94% below |
DRIO is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over DRIO on trend strength, trading above more of its moving averages.
DRIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $126.0 | $263.4 | +109% |
| 2021 | $263.4 | $273.0 | +3.6% |
| 2022 | $273.0 | $79.8 | -71% |
| 2023 | $79.8 | $34.4 | -57% |
| 2024 | $34.4 | $13.9 | -60% |
| 2025 | $13.9 | $10.0 | -28% |
| 2026 YTD | $10.0 | $1.65 | -84% |
DRIO has finished four years in a row lower, and it's down 84% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over DRIO on returns for 2026, with the stronger performance.